claim
Anti-PD-1/PD-L1 administration ameliorates age-associated functional decline in vivo, including decreased senescence-associated secretory phenotypes (SASPs) and inflammation, while improving alveolar volume, liver fat accumulation, grip strength, and athletic ability.

Authors

Sources

Referenced by nodes (2)